Ultragenyx Pharmaceutical Inc. RARE
16.41 USD +0.98 (+6.35%)
At closeNov 9, 2026, 4:01 PM EST
16.41 0.00 0.00%
After hours · Nov 9, 4:01 PM ET
15.32 Day range 16.51
12.73 52-week range 39.89
- YTD
- -28.65%
- 1 year
- -46.43%
Analyst view
Consensus: buy
Buy
Price target (mean) 25.35 +54.5% upside
Now 16.41
- Target (low)
- 16.00
- Target (mean)
- 25.35
- Target (high)
- 39.00
Ratings (0m) 21 10 buy · 11 hold · 0 sell
- Strong buy2
- Buy8
- Hold11
- Sell0
- Strong sell0
Recommendation trend
- This month 21
- 1 month ago 21
- 2 months ago 20
- 3 months ago 20
Earnings and revenue estimates
Consensus for the coming quarters and fiscal years
| Period | EPS estimate | Low – high | Year ago | EPS growth | Revenue estimate | Revenue growth | Analysts |
|---|---|---|---|---|---|---|---|
| Current quarter | 0.39335 | -1.04 – 2.46 | -1.29 | +130.5% | 234.09M | +13.1% | 6 |
| Next quarter | -0.23 | -0.45 – 0.06 | -1.54 | +85.1% | 184.53M | +35.7% | 3 |
| Current year | -2.99 | -4.92 – -1.07 | -5.83 | +48.6% | 758.50M | +12.7% | 6 |
| Next year | 1.12 | -0.3915 – 4.50 | -2.99 | +137.4% | 978.93M | +29.1% | 6 |
Upgrades and downgrades
The latest rating changes
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Nov 5, 2026 | Citigroup | Maintained | Buy | Buy |
| Nov 5, 2026 | Barclays | Maintained | Overweight | Overweight |
| Nov 4, 2026 | Canaccord Genuity | Maintained | Buy | Buy |
| Nov 4, 2026 | TD Cowen | Maintained | Buy | Buy |
| Nov 4, 2026 | Morgan Stanley | Maintained | Equal-Weight | Equal-Weight |
| Nov 4, 2026 | Goldman Sachs | Maintained | Neutral | Neutral |
| Nov 4, 2026 | Wells Fargo | Maintained | Equal-Weight | Equal-Weight |
| Nov 4, 2026 | Wedbush | Maintained | Neutral | Neutral |
| Oct 15, 2026 | UBS | Initiated | — | Neutral |
| Sep 21, 2026 | Evercore ISI Group | Maintained | In-Line | In-Line |
| Sep 21, 2026 | Barclays | Maintained | Overweight | Overweight |
| Sep 18, 2026 | Morgan Stanley | Maintained | Equal-Weight | Equal-Weight |
| Sep 18, 2026 | Citigroup | Maintained | Buy | Buy |
| Sep 18, 2026 | Canaccord Genuity | Maintained | Buy | Buy |
| Sep 18, 2026 | Cantor Fitzgerald | Maintained | Overweight | Overweight |
| Sep 17, 2026 | Citigroup | Maintained | Buy | Buy |
| Sep 4, 2026 | Goldman Sachs | Maintained | Neutral | Neutral |
| Sep 4, 2026 | Barclays | Maintained | Overweight | Overweight |
| Sep 3, 2026 | JP Morgan | Downgrade | Overweight | Neutral |
| Sep 3, 2026 | Jefferies | Maintained | Buy | Buy |
| Sep 3, 2026 | William Blair | Downgrade | Outperform | Market Perform |
| Sep 3, 2026 | Citigroup | Maintained | Buy | Buy |
| Sep 3, 2026 | TD Cowen | Maintained | Buy | Buy |
| Sep 3, 2026 | Wells Fargo | Downgrade | Overweight | Equal-Weight |
| Sep 3, 2026 | Canaccord Genuity | Maintained | Buy | Buy |
| Sep 3, 2026 | Wedbush | Maintained | Neutral | Neutral |
| Sep 3, 2026 | Evercore ISI Group | Downgrade | Outperform | In-Line |
| Sep 3, 2026 | Baird | Downgrade | Outperform | Neutral |
| Sep 3, 2026 | HC Wainwright & Co. | Maintained | Buy | Buy |
| Sep 3, 2026 | Cantor Fitzgerald | Maintained | Overweight | Overweight |
